Immunocore Holdings plc Increase (Decrease) in Prepaid Expense and Other Assets
Immunocore Holdings plc (IMCR) reported Increase (Decrease) in Prepaid Expense and Other Assets of $16.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- Immunocore Holdings plc increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$2.10M.
- Immunocore Holdings plc increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $18.77M, a 66942.86% increase year-over-year.
- Immunocore Holdings plc increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $1.02M, a 82.14% decline year-over-year.
- Immunocore Holdings plc increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $6.09M, a 228.78% increase year-over-year.
- Immunocore Holdings plc increase (decrease) in prepaid expense and other assets for fiscal 2025 was $6.74M, a 41.90% decline from fiscal 2024.
- Immunocore Holdings plc increase (decrease) in prepaid expense and other assets for fiscal 2024 was $11.60M.
- Immunocore Holdings plc increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$8.54M, a 158.15% decline from fiscal 2022.
- Immunocore Holdings plc increase (decrease) in prepaid expense and other assets for fiscal 2022 was $14.69M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $16.68M 10-Q · filed 2026-08-06 | $17.69M derived: sum of 3 quarters · filed 2026-08-06 | $23.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $18.77M 10-Q · filed 2026-05-06 | $19.79M derived: sum of 2 quarters · filed 2026-05-06 | $25.88M derived: sum of 3 quarters · filed 2026-05-06 | $25.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.11M derived: sum of 2 quarters · filed 2026-02-25 | $6.71M derived: sum of 3 quarters · filed 2026-08-06 | $6.74M 10-K · filed 2026-02-25 |
| 2025-09-30 | $6.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.70M derived: sum of 2 quarters · filed 2026-08-06 | $5.72M 10-Q · filed 2025-11-06 | $11.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$393.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$365.00K 10-Q · filed 2026-08-06 | $5.33M derived: sum of 3 quarters · filed 2026-08-06 | $7.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $28.00K 10-Q · filed 2026-05-06 | $5.72M derived: sum of 2 quarters · filed 2026-05-06 | $7.57M derived: sum of 3 quarters · filed 2026-05-06 | $9.81M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $5.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.54M derived: sum of 2 quarters · filed 2026-02-25 | $9.78M derived: sum of 3 quarters · filed 2026-02-25 | $11.60M 10-K · filed 2026-02-25 |
| 2024-09-30 | $1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.09M derived: sum of 2 quarters · filed 2025-11-06 | $5.91M 10-Q · filed 2025-11-06 | $15.42M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.06M 10-Q · filed 2025-08-07 | $13.56M derived: sum of 3 quarters · filed 2026-02-25 | $11.22M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $1.82M 10-Q · filed 2025-05-07 | $11.32M derived: sum of 2 quarters · filed 2026-02-25 | $8.98M derived: sum of 3 quarters · filed 2026-02-25 | $11.41M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $9.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.16M derived: sum of 2 quarters · filed 2026-02-25 | $9.60M derived: sum of 3 quarters · filed 2026-02-25 | -$8.54M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $90.00K derived: sum of 2 quarters · filed 2024-11-06 | -$18.05M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$15.70M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$18.14M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $14.69M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$1.35M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |